![Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes | Journal of Hematology & Oncology | Full Text Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01166-3/MediaObjects/13045_2021_1166_Fig2_HTML.png)
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes | Journal of Hematology & Oncology | Full Text
![Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in β<sub>2</sub>AR-cAMP Responsiveness in Murine Hearts. - Abstract - Europe PMC Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in β<sub>2</sub>AR-cAMP Responsiveness in Murine Hearts. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5912947/bin/gr2.jpg)
Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in β<sub>2</sub>AR-cAMP Responsiveness in Murine Hearts. - Abstract - Europe PMC
![PDF) Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: A subanalysis from a phase 3 trial (MPACT) PDF) Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: A subanalysis from a phase 3 trial (MPACT)](https://i1.rgstatic.net/publication/309344816_Efficacy_and_safety_profile_of_nab-paclitaxel_plus_gemcitabine_in_patients_with_metastatic_pancreatic_cancer_treated_to_disease_progression_A_subanalysis_from_a_phase_3_trial_MPACT/links/5fc212e6a6fdcc6cc6778d26/largepreview.png)
PDF) Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: A subanalysis from a phase 3 trial (MPACT)
![Biomedicines | Free Full-Text | Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials | HTML Biomedicines | Free Full-Text | Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials | HTML](https://www.mdpi.com/biomedicines/biomedicines-04-00020/article_deploy/html/images/biomedicines-04-00020-g001.png)
Biomedicines | Free Full-Text | Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials | HTML
![Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes | Journal of Hematology & Oncology | Full Text Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01166-3/MediaObjects/13045_2021_1166_Fig1_HTML.png)